| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer |
|
Medicine details |
|
| Medicine name | enzalutamide (Xtandi®) |
| Formulation | 40 mg capsule |
| Reference number | 2483 |
| Indication | Treatment of adult men with high-risk non-metastatic, castration-resistant prostate cancer (CRPC) |
| Company | Astellas Pharma Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/01/2019 |
| NICE guidance | TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer |